The number of shares outstanding of each of the issuer's classes of common stock, as of September 20, 2011 was 985,468,507.
The number of shares outstanding of each of the issuer's classes of equity as of February 17, 2012: 1,458,049,852 shares of common stock,
The number of shares outstanding of each of the issuer's classes of equity as of May 18, 2012: 2,422,630,676 shares of common stock
As of August 1, 2012, there were issued and outstanding (i) 3,845,518,607 shares of our Common Stock
The number of shares outstanding of each of the issuer's classes of equity as of October 10, 2012, was 7,287,218,961. UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14C INFORMATION
http://www.sec.gov/Archives/edgar/data/790652/000079065212000043/pre14c_103012.htm
THIS INFORMATION STATEMENT IS BEING PROVIDED TO
YOU BY THE BOARD OF DIRECTORS OF IMAGING DIAGNOSTIC SYSTEMS, INC.
WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE
REQUESTED NOT TO SEND US A PROXY Imaging Diagnostic Systems, Inc.
5307, NW 35th Terrace
Fort Lauderdale, FL 33309
(954) 581-9800
INFORMATION STATEMENT
(Preliminary)
October 30, 2012
NOTICE OF STOCKHOLDER ACTION BY WRITTEN CONSENT GENERAL INFORMATION
To the Holders of Common Stock of Imaging Diagnostic Systems, Inc.:
This Information Statement has been filed with the Securities and Exchange Commission and is being furnished, pursuant to Section 14C of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to the holders (the "Stockholders") of common stock, no par value per share (the "Common Stock"), of Imaging Diagnostic Systems, Inc., a Florida corporation (the "Company"), to notify the Stockholders that on October 30, 2012, the Company received a unanimous written consent in lieu of a meeting of the holders of Series Q Preferred Stock, no par value per share (the "Series Q Preferred"), created by unanimous written consent of the Board of Directors of the Company (the "Board"), as permitted by the Company's Certificate of Incorporation, as may be amended (the "Certificate"). Each share of Series Q Preferred has the equivalent of 168,395,349 votes of Common Stock (based upon the outstanding number of shares of Common Stock issued at the time hereof).
Currently, there is one holder of Series Q Preferred (the "Series Q Stockholder" or the "Majority Stockholder"), holding fifty-one (51) shares of Series Q Preferred, resulting in the Series Q Stockholder holding in the aggregate approximately 50.9989% of the total voting power of all issued and outstanding voting capital of the Company. The Series Q Stockholder authorized the following: ·
The 1-for-500 reverse stock split of the Company's issued and outstanding shares of Common Stock (the "Reverse Stock Split");
On October 30, 2012, the Board approved the Reverse Stock Split and recommended to the Majority Stockholder that she approve the Reverse Stock Split. On October 30, 2012, the Majority Stockholder approved the Reverse Stock Split by written consent in lieu of a meeting, in accordance with Florida law. Accordingly, your consent is not required and is not being solicited in connection with the approval of the Reverse Stock Split. We will mail the Notice of Stockholder Action by Written Consent to the Stockholders on or about November 9, 2012.
WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND A PROXY.
http://www.imds.com
CTLM® - Laser Breast Imaging Without Compression
CTLM, an exciting new way of looking at breast abnormalities.
CTLM stands for Computed Tomography Laser Mammography and is a method of looking at the blood flow to the breast. Since newly forming tumors have increased blood flow, CTLM may be the answer to locating angiogenesis which can be hidden in routine mammography. Additionally, dense breast tissue is easily imaged providing the physician with additional information that mammography is unable to provide.
Facts About CTLM And Optical Imaging
- CT laser breast imaging is part of the emerging field of optical imaging.
- CTLM images blood flow to the breast and thereby should visualize Tumor Angiogenesis.
- CTLM does not use ionizing radiation (no x-rays).
- CTLM images through implants and dense breast tissue easily, unlike mammography which has difficulty penetrating very dense tissue.
- There is NO breast compression with CTLM and the breast hangs in the machine opening in it's natural position.
- In a study of over 100 women, including 30 with breast cancer, optical imaging increased sensitivity and specificity of breast cancer detection by more than 90% (Britton Chance, Molecular Imaging, Vol. 2 #2)
- The average scan time is about 10-12 minutes per breast.
- CTLM may provide a brighter future for cancer patients due to earlier diagnosis and treatment. Early visualization of tumors in the evolving process may aid in the early detection of breast cancer.
An innovative breast imaging system to aid in the detection of breast abnormalities.
Shouldn't there be a less invasive way to see breast abnormalities? CTLM, an exciting new way of looking at breast abnormalities, may be the answer. CTLM stands for Computed Tomography Laser Mammography and is a method of looking at the blood flow to the breast. Since newly forming tumors have increased blood flow, CTLM may be the answer to imaging angiogenesis which can be hidden in routine mammography specifically with the dense breast patients. In addition, the CTLM's laser is not impeded by dense breast. And unlike other modalities such as Breast MRI, a contrast agent is not needed with the CTLM.
CTLM Examination...
The patient lies comfortably in the prone position with one breast suspended in the scanning aperture. A laser beam sweeps 360 degrees around the breast while the data acquired is processed and reconstructed into Multiplanar and 3D images of the breast. The examination which takes approximately 12 minutes per breast does not require breast compression or an injection. The CTLM system images the angioegenic blood supply by detecting the presence of increased hemoglobin in the imaging field. This increase of hemoglobin known as angiogenesis is used as an early indication of cancer.
Additionally, since there is no radiation, high-risk or patients with abnormalities could be imaged more often to decrease the patient's anxiety and increase the doctor's chance of early detection of breast abnormalities.
The patent for the CTLM® was issued in December 1997 under Patent Number 5,692,511 (the "Patent").
The Patent has a total of 4 independent claims and 24 subordinate claims. The independent claims serve to provide an overall outline of the disclosure of the invention. The subordinate claims provide additional information to identify pertinent details of the invention as they relate to the respective specific independent claim. We own the rights to the Patent for its 17-year life pursuant to an exclusive patent licensing agreement with the late Richard Grable, who invented the CTLM and served as our Chief Executive Officer and whose estate has owned the Patent since his death in August 2001. As of the date of this report, we own 20 patents and have 3 additional United States patents pending with regard to optical tomography, many of which are based on the original CTLM technology. We also have 15 International patents and have 8 International patents pending.
-
September 1999
, we were issued a patent for a laser imaging apparatus using biomedical markers that bind to cancer cells. This patent was issued under Patent Number 5,952,664 and is owned by the Company. The biomedical marker we are currently testing is a fluorescent marker. We plan to continue studying other biomedical markers in conjunction with major pharmaceutical companies as a potential advanced diagnostic feature to be used with our CTLM system. The CTLM in combination with the fluorescent feature has the potential to be used with photodynamic therapy (PDT) to aid in the treatment of breast cancer. -
February 2000
, we were issued a patent for: "Device for Determining the Perimeter of the Surface of an Object Being Scanned and for Limiting Reflection from the Object Surface". The patent was issued under Patent Number 6,029,077 and is owned by the Company. This particular patent covers the technique for determining the perimeter of the breast, which simplifies the algorithms necessary to produce the image. -
March 2000
, we were issued a patent for: "Apparatus and Method for Determining the Perimeter of the Surface of an Object Being Scanned". The patent was issued under Patent Number 6,044,288, and is owned by the Company. This additional patent covers an optical technique to determine the perimeter of a scanned breast. The Company's patent 6,029,077 described in the previous paragraph covers a different technique to perform the same measurement. Together, these two patents protect the practical techniques that can be used to acquire this information. -
August 2000
, we were issued a patent for: "Detector Array for Use in a Laser Imaging Apparatus". The patent was issued under Patent Number 6,100,520 and is owned by the Company. This patent describes the several different variations that can be used while scanning the breast without any contact between the breast and the optical components. Unlike the conventional method, this unique feature allows the CTLM to scan the breast without the use of breast compression. -
October 2000
, we were issued a patent for: "Method of Reconstructing an Image Being Scanned". The patent was issued under Patent Number 6,130,958 and is owned by the Company. This patent describes the algorithms used to reconstruct images from data acquired from CTLM scans. -
December 2000
, we were issued a patent for: "Detector Array With Variable Gain Amplifiers For Use In A Laser Imaging Apparatus". The patent was issued under Patent Number 6,150,649 and is owned by the Company. This patent describes the proprietary electronics used in the CTLM detector array. -
February 2001
, Mr. Grable was issued a patent for "Diagnostic Tomographic Laser Imaging Apparatus". This patent was issued for his proprietary scanning bed, a unique feature of the CTLM, and was issued as U.S. Patent Number 6,195,580. The patent allows for a fixed horizontal platform including a top surface with an opening through which the female breast is vertically pendent using a laser beam for the detection of breast abnormalities. The patent should prevent others in the industry from utilizing a scanning bed with a laser breast imaging system that requires the patient to lie in the prone position. See "Patent Licensing Agreement". -
April 2001
, we were issued a patent for: "Detector Array for Use in a Laser Imaging Apparatus". The patent was issued under Patent No. 6,211,512 and is owned by the Company. The patent allows for several different optics variations while scanning the breast without contact between the breast and the optical components. This feature allows the CTLM to scan the breast without the use of breast compression. -
January 2002
, we announced that we were issued a patent for "Detector Array With Variable Gain Amplifiers for Use in a Laser Imaging Apparatus," as U.S. Patent No. 6,331,700. This patent protects some of the non-obvious, but essential, design aspects of an optical CT scanner. This patent addresses the solution to the problem of accommodating a huge dynamic range of light intensities emitted from the breast. -
February 2002
, we were issued a patent for "Time-Resolved Breast Imaging Device," as U.S. Patent No. 6,339,216. This patent protects the key electronics of a time-resolved optical CT scanner. It addresses the solution to the problem of simultaneously accommodating a large dynamic range of light intensities emitted from the breast while achieving the necessary temporal resolution. -
May 2003
, we were issued a patent for "Medical Optical Imaging Scanner Using Multiple Wavelength Simultaneous Data Acquisition for Breast Imaging," as U.S. Patent No. 6,571,116. -
January 2004
, we announced that we were issued a patent for "PHANTOM FOR OPTICAL AND MAGNETIC RESONANCE IMAGING QUALITY CONTROL," as U.S. Patent No. 6,675,035. This invention relates to phantoms for use in optical and magnetic resonance imaging that emulates the optical characteristics of breast tissue, that resembles the breast in shape and size, as an integral component of a quality assurance protocol to verify the performance of the medical imaging apparatus being evaluated. -
January 2004
, we announced that we were issued a patent for "METHOD FOR IMPROVING THE ACCURACY OF DATA OBTAINED IN A LASER IMAGING APPARATUS," as U.S. Patent No. 6,681,130. This method improves the accuracy of data obtained using a diagnostic medical imaging apparatus that employs a near-infrared laser and array of detectors with variable gain amplifiers that can accommodate the wide dynamic range of signals available from the detectors. -
February 2004
, we announced that we were issued a patent for "LASER IMAGING APPARATUS USING BIOMEDICAL MARKERS THAT BIND TO CANCER CELLS" as U.S. Patent No. 6,693,287. This patent protects the proprietary method of collecting data while using "biomedical" markers that bind to cancer cells during a CT laser scan to provide a positive identification of the cancer area, to selectively activate the Photo Dynamic Therapy (PDT) drug to destroy the cancer. -
April 2004
, we announced that we were granted a Canadian Patent for "LASER IMAGING APPARATUS USING BIOMEDICAL MARKERS THAT BIND TO CANCER CELLS" as Canadian Patent No. 2,373,299. This patent broadly covers the optical imaging of fluorescent compounds. -
May 2004
, we announced that we were issued a patent for "MEDICAL OPTICAL IMAGING SCANNER USING MULTIPLE WAVELENGTH SIMULTANEOUS DATA ACQUISITIONS FOR BREAST IMAGING" as Patent No. 6,738,658. This patent protects the concept of differential reconstruction: reconstructing the difference in data before and after an injection of a contrast agent, such as a fluorescent compound. -
June 2004
, we announced that we were granted a Chinese Patent for "DIAGNOSTIC TOMOGRAPHIC LASER IMAGING APPARATUS" as Chinese Patent No. ZL95197940X. The patent was issued in the name of Richard J. Grable for a period of 20 years from the date of filing until July 10, 2015 and is exclusively licensed to Imaging Diagnostic Systems, Inc. See "Patent Licensing Agreement". -
August 2004
, we announced that we were granted a European Patent for "APPARATUS FOR DETERMINING THE PERIMETER OF THE SURFACE OF AN OBJECT BEING SCANNED" as European Patent No. 1003419. This is the European equivalent of U.S. Patent No. 6,044,288, which protects a key element in the optical technique used to determine the perimeter of an object being scanned.
We intend to file for patents on products, including the CTLM, for which we believe the cost of obtaining a patent is economically reasonable in relation to the expected protection obtained.
CTLM Distributors
-
Austria
- Lebada USA
Tel: 954-594-2409 -
Australia
- Jainsons Pty Ltd
Tel: +60173975895 -
Brazil
- Ultra-X/Newport
Tel: +553134635140 -
Bulgaria
- Lebada USA
Tel: 954-594-2409 -
Canada
- Arc Diagnostics Inc.
Tel: 416-521-9888 -
Croatia
- Medigala d.o.o.
Tel: +381112631941 -
Dubai UAE
- European Medical Equipment Distribution ME
Tel: +97143635368 -
Ecuador
- Biocare Medica S.A.
Tel: +59304335912 -
Hungary
- Kardia Hungary
Tel: +36309318100 -
India
- High Tech Health
Tel: +0222674408 -
- India- Jainsons Pty Ltd
Tel: +60173975895
-
ndonesia
- Jainsons Pty Ltd
Tel: +60173975895 -
Israel
- Oyamo Group
Tel: +972544774747 -
Italy
- Biomedical International
Tel: +393488816530 -
Malaysia
- Daichi Holding Berhad
Tel: +6042291811 -
Poland
- EDO MED Sp.z.o.o
Tel: +48226416109 -
Serbia
- Medigala d.o.o.
Tel: +003811122631941 -
Slovenia
- Medigala d.o.o.
Tel: +381112631941 -
Republic of Moldova
- Lebada USA
Tel: 954-594-2409 -
Romania
- Lebada USA
Tel: 954-594-2409 -
Ukraine
- Lebada USA
Tel: +393488816530
Location: Miami Beach, Florida - Miami Beach Convention Center
About: FIME is the Largest International Medical Trade Fair and Congress in the United States. Registrants from around the world and from all specialties and disciplines of the total health care arena attend FIME to see the latest medical equipment, products, supplies, technology and services and learn from industry experts in the three-day five track educational conference.
Companies exhibit at FIME primarily to generate high volume sales. The annual event is a purchasing show catering to conventional distributor networks, group purchasing organizations, integrated delivery networks, hospitals, imaging centers, private practice facilities, and HME/DME providers. The dynamic attendee base is key to penetrating and navigating around complicated medical distribution channels and networks. Exhibit floor focused, FIME flat-out gets products to market
~~~~~~~~~~~ MOST RECENT NEWS ~~~~~~~~~~~~~~
Imaging Diagnostic Signs Shimadzu Medical to Market Its CTLM(R) Laser Breast Imaging Device in Australia, New Zealand and the Pacific Islands
FORT LAUDERDALE, FL, May 14, 2012 (MARKETWIRE via COMTEX) -- Imaging Diagnostic Systems, Inc. (OTCBB: IMDS), a pioneer in laser breast imaging, announced today that it has signed a distribution agreement with Shimadzu Medical to market and sell its Computed Tomography Laser Mammography (CTLM(R)) System in Australia, New Zealand and the Pacific Islands.
"This strategic move follows in line with our vision to be in the forefront of innovative technologies that will further enhance our business. The Directors of Shimadzu Corporation unanimously agreed that the CTLM(R) system could heighten our image in the breast imaging realm. IDSI has developed a high quality innovative breast imaging product that will expand our product range. Shimadzu is well positioned to provide ongoing sales, service and support for the CTLM given our history and expertise in the medical device arena. We are excited to make this innovative technology available to women in Australia, New Zealand and the Pacific Islands," commented Nick Mascoulis, General Manager/Shimadzu Medical Systems (Oceania) P/L.
Shimadzu Medical Systems (Oceania) Pty Ltd is an Australasian subsidiary of Shimadzu Corporation, Kyoto, Japan. Shimadzu's goal is to support a healthy, comfortable living for all people. They have strived to contribute to people's health and well-being since their inception in 1875. Shimadzu focuses on the development of "molecular imaging technology" to enable detection of subtle symptoms before the onset of full-blown diseases.
Linda Grable, CEO of Imaging Diagnostic Systems, Inc., states, "IDSI is very excited to appoint Shimadzu Corporation, a leader of global technologies, as the distributor in Australia, New Zealand and the Pacific Islands. We are eager to work with Shimadzu to make CTLM(R) available to women in that part of the globe."
Imaging Diagnostic's Non-Invasive CTLM(R) Laser Breast Imaging Device Will Soon Be Available to Women in Kuwait
FORT LAUDERDALE, FL, May 22, 2012 (MARKETWIRE via COMTEX) -- Imaging Diagnostic Systems, Inc. IMDS 0.00% , a pioneer in laser breast imaging, announced today that it has signed a distribution agreement with Mareen Group to market and sell its Computed Tomography Laser Mammography (CTLM(R)) System in Kuwait.
"Mareen Group is honored to present the CTLM(R) to the women of Kuwait. We are eager to support the imaging needs of patients through this dignified and innovative laser breast imaging modality," commented Ahmad Abdulrahman, General Manager of Mareen Group.
Mareen Group is a Medical & Pharmaceutical distribution company well established and based in Kuwait. They have been in operation since 1998, proudly providing various medical and healthcare institutions within Kuwait and the surrounding areas with advanced medical equipment and pharmaceuticals from across the globe. The philosophy of Mareen Group has always been to build close ties with their customers by supporting their every need with prompt professional service and support.
Imaging Diagnostic's CEO, Linda Grable, states, "IDSI is delighted to assign Mareen Group, a well established medical company in Kuwait, as our new distributor. The women in Kuwait will hopefully benefit from CTLM(R)'s unique and discrete breast imaging process to aid in the diagnosis and management of breast abnormalities. We are enthusiastic to work with Mareen Group to make the CTLM(R), a non-invasive alternative, accessible to women in Kuwait."
Information on IMDS's distributor to four European countries
CTLM Distributors
Austria - Lebada USA
Tel: +954-594-2409
Republic of Moldova - Lebada USA
Tel: +954-594-2409
Romania - Lebada USA
Tel: +954-594-2409
Ukraine - Lebada USA
Tel: +954-594-2409
Hungarian International Tabernacle Center
Mailing Address: 1581 NW 132nd Ave
Pembroke Pines, FL 33028-
Street Address: 12401 Stirling Rd
Cooper City, FL 33330-
Phone: (954) 594-2409
Pastor: Rev. Ovidiu T. Lebada
Eurolifecare.com
Registrant:
Ovidiu T. Lebada
1581 MW 132 Ave
Pembroke Pines, Florida 33028
United States
Registered through: GoDaddy.com, LLC (http://www.godaddy.com)
Domain Name: EUROLIFECARE.COM
Created on: 25-Aug-10
Expires on: 25-Aug-12
Last Updated on: 22-Aug-11
Administrative Contact:
Lebada, Ovidiu T. lebadausa@comcast.net
1581 MW 132 Ave
Pembroke Pines, Florida 33028
United States
(954) 594-2409
Technical Contact:
Lebada, Ovidiu T. lebadausa@comcast.net
1581 MW 132 Ave
Pembroke Pines, Florida 33028
United States
(954) 594-2409
http://start.cortera.com/company/research/k5l8nql0p/lebada-usa-inc/
LEBADA USA INC
1581 NW 132ND AVE
PEMBROKE PINES, FL 33028-2741 |
COMPANY DETAILS
Location Type: Single Location
Industry: Food Preparations, N.E.C.
Ownership: Private
Year Founded: 2003
Sales Range: Under $500,000
Employees: 1 to 5
LEBADA USA INC is in the Food Preparations, N.E.C. industry in PEMBROKE PINES, FL. This company currently has approximately 1 to 5 employees and annual sales of Under $500,000.
IMDS SHARE STRUCTURE The number of shares outstanding of each of the issuer's classes of common stock, as of September 20, 2011 was 985,468,507.
The number of shares outstanding of each of the issuer's classes of equity as of February 17, 2012: 1,458,049,852 shares of common stock,
The number of shares outstanding of each of the issuer's classes of equity as of May 18, 2012: 2,422,630,676 shares of common stock
As of August 1, 2012, there were issued and outstanding (i) 3,845,518,607 shares of our Common Stock
The number of shares outstanding of each of the issuer's classes of equity as of October 10, 2012, was 7,287,218,961.